Health-related quality of life in French adults with X-linked hypophosphatemia: real-world data from the International XLH Registry

Read full text Summarise with VIRAT
Authors: Karine Briot, Sandrine Lemoine, Bernard Cortet, Paulina Szafors, Nadia Mehsen, Guillaume Couture, Kerry Sandilands, Angela Rylands, Haruka Ishii, Annabel Bowden, Jennifer E. Dent, Peter Kamenický
Cited by: 0
References: 38

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract X-linked hypophosphatemia (XLH) is a rare genetic condition in which excess fibroblast growth factor 23 causes renal phosphate wasting, leading to skeletal morbidities. Patients experience musculoskeletal pain, stiffness, and fatigue, with impaired physical function and health-related quality of life (HRQL). Burosumab has been available in France for the treatment of XLH since 2021; European treatment guidelines suggest use in adults with pseudofractures or with insufficient response and/or intolerance to oral phosphate supplements and active vitamin D. The International XLH Registry is collecting long-term observational data in a real-world setting from patients with XLH. Here, we report data from French adults from their first completion of the Short-Form 36 (SF-36) version 2 health survey, a measure of health-related quality of life. The analysis used data from 123 adults who completed the survey at least once (73% women; mean age at completion 42.5 yr [SD 13.4]; mean age at diagnosis 8.8 [12.6] yr). Group mean T-scores in the current International XLH Registry sample were

Fields of Study & Subjects

Parathyroid Disorders and Treatments Health Systems Economic Evaluations Quality of Life Bone health and osteoporosis research

Publication details

Journal / source
JBMR Plus
Volume
10
Issue
5
Pages
ziag050–ziag050
Publication date
25 March 2026
Language
EN